Picard F, Sokoloff A, Pham V, et al. - Researchers assessed the benefit as well as the safety of glycoprotein IIb/IIIa inhibitor (GPi) use in out of hospital cardiac arrest (OHCA) patients needing percutaneous coronary intervention (PCI). This analysis involved 385 patients. In 41.3% of cases (159 patients), GPi were given. Younger age, less prior PCI, more often a TIMI 0 or 1 flow prior to PCI and thromboaspiration use, all were noted in patients treated with GPi. As per findings, GPi use in patients managed with PCI for OHCA from cardiac cause was shown to be related to an elevated risk of major bleeding events, without difference in in-hospital stent thrombosis or mortality.